March 27th 2024
Data from the phase 2 AUGMENT-101 trial support the biologics license application for revumenib in patients with relapsed/refractory KMT2A-rearranged acute leukemia.
Expert Illustrations and Commentaries™: Evaluating the Potential for Novel Mechanistic Approaches to Overcome Clinical Gaps in the Care of Patients with LR-MDS
View More
Medical Crossfire®: Expert Perspectives in Geographic Atrophy – How Can We Prepare for a New Era of Treatment?
View More
Clinical Vignettes™: Integrating Novel CAR T-Cell Therapies Across Lymphoid Malignancies with an Eye Toward the Future of Care
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Mogamulizumab May Benefit Patients with Cutaneous T-Cell Lymphoma
December 12th 2017A study presented at the 2017 ASH annual meeting showed that mogamulizumab resulted in significantly superior progression free survival and better outcomes compared with vorinostat in patients with previously treated CTCL.
Combination Therapy Proposed for Multiple Myeloma and Mantle Cell Lymphoma
December 12th 2017A proof-of-concept study has demonstrated that resistance to treatment in multiple myeloma and mantle cell lymphoma could be linked to a protein called Nrf1, which appears to respond to proteasome insufficiency or pharmacological inhibition.
Translocation (1;19) in Adult B-Cell ALL Linked With Favorable Outcomes
December 11th 2017Adults with Philadelphia chromosome–negative B-cell acute lymphoblastic leukemia are very likely to achieve complete response with intensive combination induction chemotherapy, according to a retrospective review presented at the ASH Annual Meeting.
Selinexor Plus Sorafenib May Benefit Patients with Relapsed/Refractory FLT3-Mutated AML
December 11th 2017Data presented at the 2017 ASH annual meeting revealed that the combination of selinexor and sorafenib appears to be safe with clinical activity in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia.
Six-Month Analysis of CTL019 Demonstrates Sustained Responses in Refractory DLBCL Patients
December 11th 2017A potentially practice-changing study presented at 2017 ASH shows high rates of sustained complete response in patients with relapsed/refractory diffuse large B-cell lymphoma who were treated with CTL019 CAR T-cell therapy.
Mogamulizumab May Benefit Patients with Cutaneous T-Cell Lymphoma
December 11th 2017Data presented at 2017 ASH showed that mogamulizumab resulted in improved progression free survival (PFS), overall response rates (ORR), and better quality of life in patients with previously treated CTCL compared with vorinostat.
Combination Ibrutinib/Venetoclax Shows Early Promise in Previously Treated CLL
December 10th 2017About one-third of patients with previously treated chronic lymphocytic leukemia (CLL) were minimal residual disease negative after 6 months of treatment with the combination of targeted agents ibrutinib and venetoclax, according to the results of the TAP CLARITY study.
ASCO Value Framework Challenging to Apply in CLL
November 21st 2017Although the ASCO Value Framework is an important step to quantify the value of cancer therapies, a new study has found that it has essential limitations for its application in clinical practice for the treatment of chronic lymphocytic leukemia.
Radotinib for CML Yields Better Responses Than Imatinib
November 8th 2017Among patients with newly diagnosed, chronic-phase chronic myeloid leukemia, a lower-dose regimen of radotinib demonstrated superior complete cytogenetic response and major molecular response rates at 12 months compared to imatinib.
Micro RNA Risk Profile for Pediatric AML Can ID High-Risk Patients
November 5th 2017A novel risk classification scheme based on expression of 36 micro-RNA samples was able to identify pediatric patients with acute myeloid leukemia at high or low risk of experiencing treatment failure, according to a new analysis.
Good QOL Maintained in TKI-Resistant CML With Long-Term Bosutinib Treatment
October 29th 2017In patients with chronic myeloid leukemia treated with bosutinib who were resistant or intolerant to previous tyrosine kinase inhibitors, health-related quality of life was well maintained over the long term.
Gaps Found in Monitoring of Response to TKI Therapy in CML
October 4th 2017A new study found significant gaps in the monitoring of responses to tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Patients are more likely to be monitored in Europe, at academic centers, and if they are younger than 65.